SEC Form 4 · accession 0001614740-26-000012
Mirum Pharmaceuticals, Inc. · MIRM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Peetz
Officer — CHIEF EXECUTIVE OFFICER · Director
Period of report
Aug 10, 2026
Accepted (ET)
Aug 11, 2026 · 5:41 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001759425
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2026 | M | 20,000 | $2.936 | A | 214,309 | D | |
| Common StockF2 | Aug 10, 2026 | S | 11,683 | $98.51 | D | 202,626 | D | |
| Common StockF3 | Aug 10, 2026 | S | 6,017 | $99.25 | D | 196,609 | D | |
| Common StockF4 | Aug 10, 2026 | S | 2,300 | $100.14 | D | 194,309 | D | |
| Common Stock | holding | — | — | — | 187,500 | I | By The Peetz Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F5 | $2.936 | Aug 10, 2026 | M | 20,000 | D | — | Mar 11, 2029 | Common Stock | 20,000 | 88,487 | D |
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026.
- F2The weighted average sale price for the transaction reported was $98.51, and the range of prices were between $97.93 and $98.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3The weighted average sale price for the transaction reported was $99.25, and the range of prices were between $98.94 and $99.655. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4The weighted average sale price for the transaction reported was $100.14, and the range of prices were between $99.995 and $100.2425. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F5The stock option is fully vested.